The China National Medical Products Administration has approved BeiGene’s (NASDAQ:BGNE) PD-1 inhibitor tislelizumab for the treatment of Hodgkin lymphoma patients who have received at least two prior lines of therapy.
The nod is the company’s first there.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.